Guidance on age-related macular degeneration (AMD) services for commissioners and integrated care boards, providers and users has been issued by the Royal College of Ophthalmologists (RCOphth).
It updated guidance published in 2021 because of changes to service pathways and new drugs being licensed and made available for neovascular AMD.
The RCOphth said the integrated care system facilitated services to work closely with primary eye care providers and its guidance reflected this integration and highlighted areas that needed commissioning.
Guidance also updated choices of treatment options and their regimens in recognition of more options being made available in the UK.
